At the time of writing, Bristol-Myers Squibb Co [BMY] stock is trading at $50.96, up 5.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BMY shares have gain 3.89% over the last week, with a monthly amount glided 10.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bristol-Myers Squibb Co [NYSE: BMY] stock has seen the most recent analyst activity on November 13, 2025, when Scotiabank initiated its Sector Perform rating and assigned the stock a price target of $45. Previously, Daiwa Securities downgraded its rating to Neutral on August 05, 2025, and kept the price target unchanged to $42. On April 22, 2025, Piper Sandler initiated with a Overweight rating. Cantor Fitzgerald started tracking the stock assigning a Neutral rating and suggested a price target of $55 on April 22, 2025. Jefferies upgraded its rating to a Buy but $70 remained the price target by the analyst firm on December 16, 2024. In a note dated November 15, 2024, Wolfe Research initiated an Peer Perform rating.
For the past year, the stock price of Bristol-Myers Squibb Co fluctuated between $42.52 and $63.33. Currently, Wall Street analysts expect the stock to reach $53.5 within the next 12 months. Bristol-Myers Squibb Co [NYSE: BMY] shares were valued at $50.96 at the most recent close of the market. An investor can expect a potential return of 4.98% based on the average BMY price forecast.
Analyzing the BMY fundamentals
According to Bristol-Myers Squibb Co [NYSE:BMY], the company’s sales were 48.03B for trailing twelve months, which represents an -0.97% plunge. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at 0.29%, Pretax Profit Margin comes in at 0.17%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.35 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.75.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 49.81 points at the first support level, and at 48.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 51.72, and for the 2nd resistance point, it is at 52.49.
Ratios To Look Out For
It is important to note that Bristol-Myers Squibb Co [NYSE:BMY] has a current ratio of 1.27. Further, the Quick Ratio stands at 1.17, while the Cash Ratio is 0.56. Considering the valuation of this stock, the price to sales ratio is 2.16, the price to book ratio is 5.59 and price to earnings (TTM) ratio is 17.21.
Transactions by insiders
Recent insider trading involved Elkins David V, EVP, Chief Financial Officer, that happened on Sep 02 ’25 when 56000.0 shares were sold. Officer, Elkins David V completed a deal on Sep 02 ’25 to buy 56000.0 shares. Meanwhile, EVP, Corporate Affairs Short Bartie Wendy sold 378.0 shares on Aug 02 ’25.
